Biofrontera- Warrants (27/10/2026) Long Term Debt

As of the most recent data (March 2026), BFRIW shows a long-term debt of $7.2M. That compares with $4.4M in the prior-year period — up 62.7% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, BFRIW's long-term debt is now $7.2M (was $4.4M) — a 62.7% year-over-year increase. Pairing that YoY change with peer averages gives a clearer picture of whether Biofrontera- Warrants (27/10/2026) is outperforming or lagging.

Tracking BFRIW's long-term debt over time shows whether Biofrontera- Warrants (27/10/2026) is scaling, shrinking, or reshaping that part of the business. The current reading is $7.2M That compares with $4.4M in the prior-year period — up 62.7% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this long-term debt page, Stockcircle has Biofrontera- Warrants (27/10/2026)'s full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect long-term debt (currently $7.2M) with ownership activity and broader fundamentals.

Biofrontera- Warrants (27/10/2026)'s long-term debt is $7.2M; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.